title: ÐÐ¾Ð»ÑÑÐµÐ½Ð¸Ðµ Ð¸ Ñ Ð°ÑÐ°ÐºÑÐµÑÐ¸ÑÑÐ¸ÐºÐ° ÑÐµÐ°ÑÑÐ¾ÑÑÐ°Ð½ÑÐ½Ð¾Ð³Ð¾ ÐºÐ°Ð½Ð´Ð¸Ð´Ð°ÑÐ½Ð¾Ð³Ð¾ Ð²Ð°ÐºÑÐ¸Ð½Ð½Ð¾Ð³Ð¾ ÑÑÐ°Ð¼Ð¼Ð° Ð²Ð¸ÑÑÑÐ° Ð³ÑÐ¸Ð¿Ð¿Ð° Ð/Ð¡ÐÐ±33/22/PR8/1:7/2023 (H1N1pdm09) RA-56
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: Development and characterization of candidate reassortant influenza vaccine strain Ð/Ð¡ÐÐ±33/22/PR8/1:7/2023 (H1N1pdm09) (RA-56)
Creators: name: ÐÑÐ»Ð¾Ð²Ð°, Ð¡Ð¾ÑÑÑ
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2024
Subjects: Ð²Ð¸ÑÑÑ Ð³ÑÐ¸Ð¿Ð¿Ð°
ÑÐµÐ°ÑÑÐ¾ÑÑÐ°Ð½ÑÐ½ÑÐ¹ ÑÑÐ°Ð¼Ð¼
Ð³ÑÐ¸Ð¿Ð¿Ð¾Ð·Ð½ÑÐµ Ð²Ð°ÐºÑÐ¸Ð½Ñ
Ð¸Ð½Ð°ÐºÑÐ¸Ð²Ð¸ÑÐ¾Ð²Ð°Ð½Ð½ÑÐµ Ð³ÑÐ¸Ð¿Ð¿Ð¾Ð·Ð½ÑÐµ Ð²Ð°ÐºÑÐ¸Ð½Ñ
Ð¿Ð°Ð½Ð´ÐµÐ¼Ð¸ÑÐµÑÐºÐ¸Ð¹ Ð²Ð¸ÑÑÑ
Ð¿Ð¾Ð»ÑÑÐµÐ½Ð¸Ðµ ÑÐµÐ°ÑÑÐ¾ÑÑÐ°Ð½ÑÐ½Ð¾Ð³Ð¾ ÑÑÐ°Ð¼Ð¼Ð°
influenza virus
reassortant influenza virus
influenza vaccines
inactivated influenza vaccines
pandemic virus
development of reassortant influenza vaccines

description: ÐÐ°Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¿Ð¾ÑÐ²ÑÑÐµÐ½Ð° Ð¿Ð¾Ð»ÑÑÐµÐ½Ð¸Ñ Ð¸ ÑÐ°ÑÐ°ÐºÑÐµÑÐ¸ÑÑÐ¸ÐºÐµ ÑÐµÐ°ÑÑÐ¾ÑÑÐ°Ð½ÑÐ½Ð¾Ð³Ð¾ ÐºÐ°Ð½Ð´Ð¸Ð´Ð°ÑÐ½Ð¾Ð³Ð¾ Ð²Ð°ÐºÑÐ¸Ð½Ð½Ð¾Ð³Ð¾ ÑÑÐ°Ð¼Ð¼Ð° Ð/Ð¡ÐÐ±33/22/PR8/1:7/2023 (H1N1pdm09) (RA-56) Ñ Ð¿Ð¾ÑÐ»ÐµÐ´ÑÑÑÐ¸Ð¼ Ð¿Ð¾Ð»ÑÑÐµÐ½Ð¸ÐµÐ¼ Ð¿ÑÐ¾ÑÐ¾ÑÐ¸Ð¿Ð° ÐÐÐ Ð½Ð° ÐµÐ³Ð¾ Ð¾ÑÐ½Ð¾Ð²Ðµ. Ð ÐµÐ°ÑÑÐ¾ÑÑÐ°Ð½ÑÐ½ÑÐ¹ ÑÑÐ°Ð¼Ð¼ Ð¿Ð¾Ð»ÑÑÐµÐ½ Ð¼ÐµÑÐ¾Ð´Ð¾Ð¼ ÐºÐ»Ð°ÑÑÐ¸ÑÐµÑÐºÐ¾Ð¹ Ð³ÐµÐ½ÐµÑÐ¸ÐºÐ¸ Ð½Ð° Ð¾ÑÐ½Ð¾Ð²Ðµ ÑÐ¿Ð¸Ð´ÐµÐ¼Ð¸ÑÐµÑÐºÐ¾Ð³Ð¾ ÑÑÐ°Ð¼Ð¼Ð° Ð/Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³/ÐÐÐÐ-33/2022 Ð¸ ÑÐ½Ð¸Ð²ÐµÑÑÐ°Ð»ÑÐ½Ð¾Ð³Ð¾ Ð²ÑÑÐ¾ÐºÐ¾ÑÐµÐ¿ÑÐ¾Ð´ÑÐºÑÐ¸Ð²Ð½Ð¾Ð³Ð¾ Ð´Ð¾Ð½Ð¾ÑÐ° A/Puerto Rico/8/34/LGV. ÐÐ¾ÐºÐ°Ð·Ð°Ð½Ð¾, ÑÑÐ¾ Ð¿Ð¾Ð»ÑÑÐµÐ½Ð½ÑÐ¹ ÑÑÐ°Ð¼Ð¼ Ð¾Ð±Ð»Ð°Ð´Ð°ÐµÑ Ð²ÑÑÐ¾ÐºÐ¾Ð¹ ÑÐµÐ¿ÑÐ¾Ð´ÑÐºÑÐ¸Ð²Ð½Ð¾Ð¹ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÑÑ Ð² ÑÐ¸ÑÑÐµÐ¼Ðµ ÑÐ°Ð·Ð²Ð¸Ð²Ð°ÑÑÐ¸ÑÑÑ ÐºÑÑÐ¸Ð½ÑÑ ÑÐ¼Ð±ÑÐ¸Ð¾Ð½Ð¾Ð² Ð¸ ÑÑÐ°Ð±Ð¸Ð»ÑÐ½Ð¾Ð¹ ÑÐ¾ÑÐ¼ÑÐ»Ð¾Ð¹ Ð³ÐµÐ½Ð¾Ð¼Ð° 7:1 Ñ Ð³ÐµÐ¼Ð°Ð³Ð³Ð»ÑÑÐ¸Ð½Ð¸Ð½Ð¾Ð¼ Ð¾Ñ ÑÑÐ°Ð¼Ð¼Ð° Ð´Ð¸ÐºÐ¾Ð³Ð¾ ÑÐ¸Ð¿Ð°. ÐÐ¾Ð»ÑÑÐµÐ½Ð½ÑÐ¹ ÑÐµÐ°ÑÑÐ¾ÑÑÐ°Ð½ÑÐ½ÑÐ¹ ÑÑÐ°Ð¼Ð¼ Ð¾Ð±Ð»Ð°Ð´Ð°ÐµÑ ÑÐµÐ½Ð¾ÑÐ¸Ð¿Ð¸ÑÐµÑÐºÐ¸Ð¼Ð¸ ÑÐ²Ð¾Ð¹ÑÑÐ²Ð°Ð¼Ð¸ Ð½ÐµÐ¾Ð±ÑÐ¾Ð´Ð¸Ð¼ÑÐ¼Ð¸ Ð´Ð»Ñ ÑÐ°Ð·ÑÐ°Ð±Ð¾ÑÐºÐ¸ ÐÐÐ, Ð¾Ð´Ð½Ð°ÐºÐ¾ Ð¾ÑÑÑÑÑÑÐ²Ð¸Ðµ ÑÐµÐ¼Ð¿ÐµÑÐ°ÑÑÑÐ¾ÑÑÐ²ÑÑÐ²Ð¸ÑÐµÐ»ÑÐ½Ð¾Ð³Ð¾ ÑÐµÐ½Ð¾ÑÐ¸Ð¿Ð° Ð´ÐµÐ»Ð°ÐµÑ Ð¿Ð¾Ð»ÑÑÐµÐ½Ð½ÑÐ¹ ÑÑÐ°Ð¼Ð¼ Ð¿Ð¾Ð»Ð½Ð¾ÑÑÑÑ Ð½ÐµÐ¿ÑÐ¸Ð³Ð¾Ð´Ð½ÑÐ¼ Ð´Ð»Ñ ÑÐ°Ð·ÑÐ°Ð±Ð¾ÑÐºÐ¸ ÐÐÐ. ÐÐ° Ð¾ÑÐ½Ð¾Ð²Ðµ ÑÐµÐ°ÑÑÐ¾ÑÑÐ°Ð½ÑÐ½Ð¾Ð³Ð¾ ÑÑÐ°Ð¼Ð¼Ð° Ð¸Ð·Ð³Ð¾ÑÐ¾Ð²Ð»ÐµÐ½ Ð¿ÑÐ¾ÑÐ¾ÑÐ¸Ð¿ ÐÐÐ Ð¸ Ð¿Ð¾ÐºÐ°Ð·Ð°Ð½Ð° ÐµÐ³Ð¾ Ð±Ð¸Ð¾Ð»Ð¾Ð³Ð¸ÑÐµÑÐºÐ°Ñ Ð±ÐµÐ·Ð¾Ð¿Ð°ÑÐ½Ð¾ÑÑÑ Ð½Ð° Ð¼ÑÑÐ¸Ð½Ð¾Ð¹ Ð¼Ð¾Ð´ÐµÐ»Ð¸.
description: The given work is devoted to development and characterization of candidate reassortant influenza vaccine strain Ð/Ð¡ÐÐ±33/22/PR8/1:7/2023 (H1N1pdm09) (RA-56) with subsequent development of prototype of inactivated influenza vaccine based on it. Reassortant influenza virus was created using wild-type strain Ð/Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³/ÐÐÐÐ-33/2022 and universal high-yield donor strain A/Puerto Rico/8/34/LGV with method of classic genetics. It is shown that reassortant virus is high-yielding in embryonated chicken eggs and possesses stable set 7:1 genome formula with hemagglutinin inherited from wild-type parent strain. It is demonstrated that RA-56 has phenotype suitable for the development of inactivated influenza vaccine, yet lack of temperature-sensitivity makes it impossible to use RA-56 in the development of LAIV. Prototype of inactivated influenza vaccine was created on the basis of RA-56 and its biological safety was evaluated in mice model.